Candida: A review of clinical experience with lamisil◇

Dermatology

Volumn 194, Issue 1, 1997, Pages 10-13

  Zaias, N ^a  

^a Mount Sinai Hospital   (United States)

Author keywords

Competitors; Minimal inhibitory concentration; Terbinafine

Indexed keywords

ANTIFUNGAL AGENT; TERBINAFINE;

CANDIDIASIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SHORT SURVEY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; CANDIDIASIS; CLINICAL TRIALS; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; TREATMENT OUTCOME;

EID: 0030905447     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000246176     Document Type: Article

References (5)

1. Zaias N: Onychomycosis., Arch Dermatol 1972;105:263-274.
2. Jung EG., et al: Systemic treatment of skin ean-didosis: A randomised comparison of terbi-nafine and kétoconazole., Mycoses 1994:37: 361-365.
3. Jones TC., Villars VV: Lamisil* (terbinatine): High clinical efficacy in a short term treatment time and good tolerability., Przeglad Dermatol 1993;80:455-461.
4. Balfour JA., Faulds D: Terbinatine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses., Drugs 1992:43:259-284.
5. Jones TC: Treatment of dermatomycoses with topically applied allylamines: Naftifine and terbinatine., J Dermatol Treat 1989:1 (suppl 2): 29-32.